← Back to patent-cliff list
克拉霉素/雷贝拉唑钠/阿莫西林
Tier C — Watch / tradeClarithromycin/Rabeprazole Sodium/Amoxicillin
卫材株式会社
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：50S ribosomal subunit、Proton pump、PBPs
Brand：Rabecure
Indications (approved)：边缘带B细胞淋巴瘤、十二指肠溃疡、特发性血小板减少性紫癜、胃溃疡、胃炎、幽门螺杆菌感染
Regional status
US
-
EU
-
China
-
Japan
批准上市
2013-08-15
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clarithromycin/Rabeprazole Sodium/Amoxicillin?
Approved indications include: 边缘带B细胞淋巴瘤, 十二指肠溃疡, 特发性血小板减少性紫癜, 胃溃疡, 胃炎, 幽门螺杆菌感染.
When does the Clarithromycin/Rabeprazole Sodium/Amoxicillin patent expire?
No public expiry year is available for Clarithromycin/Rabeprazole Sodium/Amoxicillin yet; this page updates once verified.
How do I get a quote for Clarithromycin/Rabeprazole Sodium/Amoxicillin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24